ataluren

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) gained more than 13 percent Friday after the FDA found that the company's experimental drug to treat Duchenne muscular dystrophy may work. The FDA's Advisory Committee meeting ruled that the body of evidence for the company's ataluren...

PTC Therapeutics, Inc. (NASDAQ: PTCT) plunged as low as 4 percent off Thursday’s highs as traders circulated a report citing termination of the firm’s 2A ataluren study for Duchenne and Becker muscular dystrophies. However, a company spokesperson clarified that this was “very old...

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) soared higher by nearly 90 percent early Friday morning after the company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the renewal of the company's therapy called...

PTC Therapeutics, Inc. (NASDAQ: PTCT) shares are up another 4.2 percent in early Tuesday trading following a big 20.6 percent Monday gain. The big move in PTC shares has been driven by the FDA’s accelerated approval of Sarepta Therapeutics Inc (NASDAQ: SRPT)’s Eteplirsen for treatment...